Automated platelet induced aggregation.
To determine the degree of platelet inhibition from the use of P2Y12 inhibition drug therapies known as thienopyridines. These include Clopidogrel (Plavix), Prasugrel, Ticlopidine (Ticlid), and Ticagrelor.
180 - 376 PRU. Values less than 180 PRU may be evidence of a P2Y12 inhibitor effect.
Platelet counts less than 119K or more than 502K, and Hematocrit values less than 33% or greater than 52% can interfere with testing and valid results may not be obtained.
The P2Y12 Platelet Function assay is not intended for use with inherited platelet disorders such as von Willebrand Factor Deficiency, Glanzmann Thrombasthenia and Bernard-Soulier Syndrome.
- Ticagrelor Platelet Function Test
- Ticlopidine (Ticlid) Platelet Function Test
- Plavix Platelet Function Test
- Verify Now P2Y12
- P2Y12 Platelet Function Test
- Clopidogrel (Plavix) Platelet Function Test
- Thienopyridine Platelet Function Test
- Prasurgrel Platelet Function Test
- Brilinta (Ticagrelor)
Collect specimen in a 2.7 mL blue top (citrate 3.2%) tube using a 21 gauge or larger needle; do not use 1.8 mL tube. Mix by inversion. Do not centrifuge. Whole blood specimen should arrive at lab within 3 hours of collection; transport at room temperature. Collection of the blood through lines that have been previously flushed with heparin should be avoided. If the blood must be drawn through a VAD (vascular access device), the line should be flushed with 5 mL of saline and the first 5 mL of blood or six dead space volumes of the VAD discarded.
DO NOT SEND THROUGH PNEUMATIC TUBE SYSTEM.
Surgical Screen: Patients administered anti-platelet therapies are at risk of increased bleeding during operations. It is recommended that patients on P2Y12 inhibitors undergoing surgery or invasive procedures be tested preoperatively. Test results may aid in decisions to initiate or delay surgery, and to make preparations for additional blood product use if surgery cannot be postponed. Therapeutic Response: Variability in patient response to anti-platelet drugs is common. It is recommended that patients on P2Y12 inhibitors be tested to determine if the drug has produced the expected antiplatelet effect.